Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 20, 2024 - Issue 1
Submit an article Journal homepage
1,581
Views
0
CrossRef citations to date
0
Altmetric
Coronavirus

Impact of COVID-19 vaccination status on hospitalization and disease severity: A descriptive study in Nagasaki Prefecture, Japan

Guoxi Caia Public Health and Hygiene Research Department, Nagasaki Prefectural Institute of Environment and Public Health, Nagasaki, Japan;b Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;c Department of International Health and Medical Anthropology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, JapanView further author information
,
Shiwen Liud Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, 1 Xuefu North Road, Fuzhou, Fujian Province, ChinaView further author information
,
Yixiao Lue Department of Systems Biology and Health Statistics, School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong, ChinaView further author information
,
Yumika Takakia Public Health and Hygiene Research Department, Nagasaki Prefectural Institute of Environment and Public Health, Nagasaki, JapanView further author information
,
Fumiaki Matsumotoa Public Health and Hygiene Research Department, Nagasaki Prefectural Institute of Environment and Public Health, Nagasaki, JapanView further author information
,
Akira Yoshikawaa Public Health and Hygiene Research Department, Nagasaki Prefectural Institute of Environment and Public Health, Nagasaki, JapanView further author information
,
Toshitsugu Taguria Public Health and Hygiene Research Department, Nagasaki Prefectural Institute of Environment and Public Health, Nagasaki, JapanView further author information
,
Jianfen Xief Fujian Provincial Center for Disease Control and Prevention, Fuzhou, Fujian Province, ChinaView further author information
,
Kazuhiko Arimab Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JapanView further author information
,
Satoshi Mizukamib Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JapanView further author information
,
Jiwen Wub Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JapanView further author information
,
Taro Yamamotoc Department of International Health and Medical Anthropology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, JapanView further author information
,
Maiko Hasegawag Infectious Disease Control Office, Health & Welfare Department, Nagasaki Prefectural Government, Nagasaki, JapanView further author information
,
Nguyen Tien Huyh Institute of Research and Development, Duy Tan University, Da Nang, Vietnam;i School of Medicine and Pharmacy, Duy Tan University, Da Nang, Vietnam;j School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, JapanView further author information
,
Masaya Saitok Department of Nutrition Science, Faculty of Nursing and Nutrition, University of Nagasaki, Nagasaki, JapanView further author information
,
Shouhei Takeuchik Department of Nutrition Science, Faculty of Nursing and Nutrition, University of Nagasaki, Nagasaki, JapanView further author information
,
Kouichi Morital Department of Virology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan;m Dejima Infectious Disease Research Alliance, Nagasaki University, Nagasaki, JapanCorrespondence[email protected]
View further author information
,
Kiyoshi Aoyagib Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JapanCorrespondence[email protected]
View further author information
&
Fei Hed Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, 1 Xuefu North Road, Fuzhou, Fujian Province, China;n Fujian Provincial Key Laboratory of Tumor Microbiology, Fujian Medical University, Fujian Province, China;o Fujian Digital Tumor Data Research Center, Fujian Province, ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2322795 | Received 25 Oct 2023, Accepted 21 Feb 2024, Published online: 22 Mar 2024

References

  • Chams N, Chams, S, Badran, R, Shams, A, Araji, A, Raad, M, Mukhopadhyay, S, Stroberg, E, Duval, EJ, Barton, LM, et al. COVID-19: A multidisciplinary review. Front Public Health. 2020 Jul 29;8:383. doi:10.3389/fpubh.2020.00383B3.
  • Miyashita K, Hozumi H, Furuhashi K, Nakatani E, Inoue Y, Yasui H, Karayama M, Suzuki Y, Fujisawa T, Enomoto N, et al. Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study. Emerg MIcrobes Infec. 2023 Dec 1;12(1):2155250. doi:10.1080/22221751.2022.2155250.
  • Tomioka K, Uno K, Yamada M. Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during omicron BA.1/BA.2 and BA.5-predominant periods in Japan. Environ Health Prev. 2023 Jan 20;28:35. doi:10.1265/ehpm.23-00061.
  • Peramo-Alvarez FP, Lopez-Zuniga MA, Lopez-Ruz MA. Medical sequels of COVID-19. Med Clin-Barcelona. 2021 Oct 22;157(8):388–10. doi:10.1016/j.medcli.2021.04.023.
  • Tsuzuki S, Miyazato Y, Terada M, Morioka S, Ohmagari N, Beutels P. Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients. Health Qual Life Out. 2022 Aug 19;20(1):125. doi:10.1186/s12955-022-02033-6.
  • WHO. 2023 [accessed 9 Sep 2023]. https://www.who.int/teams/health-care-readiness/post-covid-19-condition
  • Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, Fan J, Song L, Tong Y, Fan H. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Tar. 2022 May 3;7(1):146. doi:10.1038/s41392-022-00996-y.
  • Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021 Oct 1;21(10):626–36. doi:10.1038/s41577-021-00592-1.
  • Our World in data coronavirus (COVID-19) vaccinations. 2023 [accessed 2023 Sep 9]. https://ourworldindata.org/covid-vaccinations
  • National Institute of Infectious Diseases. COVID-19 vaccine (as of May 10, 2021). https://www.tandfonline.com/doi/full/10.1080/14760584.2023.2188950; 2021 [accessed 2023 Sep 9].
  • Baden LR, El SH, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403–16. doi:10.1056/NEJMoa2035389.
  • Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–15. doi:10.1056/NEJMoa2034577.
  • Arashiro T, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, Arioka H, Yanai H, Kuramochi J, Ihara G, et al. Coronavirus disease 19 (COVID-19) vaccine effectiveness against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during delta-dominant and omicron-dominant periods in Japan: a multicenter prospective case-control study (Factors Associated with SARS-CoV-2 infection and the effectiveness of COVID-19 vaccines study). Clin Infect Dis. 2023 Feb 8;76(3):e108–15.
  • Maeda H, Saito N, Igarashi A, Ishida M, Suami K, Yagiuchi A, Kimura Y, Komino M, Arai H, Morikawa T. et al. Effectiveness of messenger RNA coronavirus disease 2019 vaccines against symptomatic severe acute respiratory syndrome coronavirus 2 infections during the delta variant epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Clin Infect Dis. 2022 Nov 30;75(11):1971–9. doi:10.1093/cid/ciac292.
  • Maeda H, Saito N, Igarashi A, Ishida M, Terada M, Ito T, Ikeda H, Kamura H, Motohashi I, Kimura Y. et al. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Expert Rev Vaccines. 2023 Jan 1;22(1):288–98. doi:10.1080/14760584.2023.2188950.
  • Tomioka K, Uno K, Yamada M. Association between vaccination status and COVID-19-related health outcomes among community-dwelling COVID-19 patients in Nara, Japan. Environ Health Prev. 2023 Jan 20;28:7. doi:10.1265/ehpm.22-00199.
  • Agrawal U, Bedston S, McCowan C, Oke J, Patterson L, Robertson C, Akbari A, Azcoaga-Lorenzo A, Bradley DT, Fagbamigbe AF, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet. 2022 Oct 15;400(10360):1305–20. doi:10.1016/S0140-6736(22)01656-7.
  • Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, Ghamande S, Douin DJ, Talbot HK, Casey JD, et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and disease severity. Jama-J Am Med Assoc. 2021 Nov 23;326(20):2043–54. doi:10.1001/jama.2021.19499.
  • von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007 Oct 20;370(9596):1453–7. doi:10.1016/S0140-6736(07)61602-X.
  • Agrawal U, Katikireddi SV, McCowan C, Mulholland RH, Azcoaga-Lorenzo A, Amele S, Fagbamigbe AF, Vasileiou E, Grange Z, Shi T, et al. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study. Lancet Resp Med. 2021 Dec 1;9(12):1439–49. doi:10.1016/S2213-2600(21)00380-5.
  • COVID-19 clinical guidelines these guidelines (Version 5.3); 2021. https://www.mhlw.go.jp/content/000829136.pdf.
  • Kosaka M, Hashimoto T, Ozaki A, Tanimoto T, Kami M. Delayed COVID-19 vaccine roll-out in Japan. Lancet. 2021 Jun 19;397(10292):2334–5. doi:10.1016/S0140-6736(21)01220-4.
  • Okamoto S, Kamimura K, Komamura K. COVID-19 vaccine hesitancy and vaccine passports: a cross-sectional conjoint experiment in Japan. BMJ Open. 2022 Jun 16;12(6):e60829. doi:10.1136/bmjopen-2022-060829.
  • Hotta K, Suzuki E, Ichihara E, Kiura K. Three doses of mRNA COVID-19 vaccine protects from SARS-CoV-2 infections in Japan. J Intern Med. 2022 Oct 1;292(4):687–9. doi:10.1111/joim.13526.
  • Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, Groome MJ, Huppert A, O’Brien KL, Smith PG. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022 Mar 5;399(10328):924–44. doi:10.1016/S0140-6736(22)00152-0.
  • Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infec. 2022 Feb 1;28(2):202–21. doi:10.1016/j.cmi.2021.10.005.
  • Wu N, Joyal-Desmarais K, Ribeiro P, Vieira AM, Stojanovic J, Sanuade C, Yip D, Bacon SL. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to december, 2022. Lancet Resp Med. 2023 May 1;11(5):439–52. doi:10.1016/S2213-2600(23)00015-2.
  • Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, Doolman R, Asraf K, Mendelson E, Ziv A, et al. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med. 2021 Dec 9;385(24):e84. doi:10.1056/NEJMoa2114583.
  • Liew F, Talwar S, Cross A, Willett BJ, Scott S, Logan N, Siggins MK, Swieboda D, Sidhu JK, Efstathiou C, et al. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine. 2023 Jan 1;87:104402. doi:10.1016/j.ebiom.2022.104402.
  • Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021 May 15;397(10287):1819–29. doi:10.1016/S0140-6736(21)00947-8.
  • Tenforde MW, Self WH, Naioti EA, Ginde AA, Douin DJ, Olson SM, Talbot HK, Casey JD, Mohr NM, Zepeski A, et al. Sustained effectiveness of pfizer-BioNTech and moderna vaccines against COVID-19 associated hospitalizations among adults — United States, March–July 2021. MMWR-Morbid Mortal W. 2021 Aug 27;70(34):1156–62. doi:10.15585/mmwr.mm7034e2.
  • Gao YD, Ding M, Dong X, Zhang JJ, Kursat AA, Azkur D, Gan H, Sun YL, Fu W, Li W, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021 Feb 1;76(2):428–55. doi:10.1111/all.14657.
  • Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, Li T, Margolick JB, Pawelec G, Leng SX. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021 Jan 1;65:101205. doi:10.1016/j.arr.2020.101205.
  • Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, Heath R, Tuner A, Friedrich Z, Morrison L. et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021 Nov 1;21(11):1539–48. doi:10.1016/S1473-3099(21)00330-3.
  • Jaisinghani P, Kumar R. Obesity and viral infections. Gastroenterol Clin N. 2023 Jun 1;52(2):393–402. doi:10.1016/j.gtc.2023.03.012.
  • Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, Wang M, Li S, Morita H, Altunbulakli C, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020 Nov 1;75(11):2829–45. doi:10.1111/all.14429.
  • Fitzgerald KC, Mecoli CA, Douglas M, Harris S, Aravidis B, Albayda J, Sotirchos ES, Hoke A, Orbai A-M, Petri M, et al. Risk factors for infection and health impacts of the coronavirus disease 2019 (COVID-19) pandemic in people with autoimmune diseases. Clin Infect Dis. 2022 Feb 11;74(3):427–36. doi:10.1093/cid/ciab407.
  • Galmiche S, Luong NL, Tartour E, de Lamballerie X, Wittkop L, Loubet P, Launay O. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infec. 2022 Feb 1;28(2):163–77. doi:10.1016/j.cmi.2021.09.036.
  • Higham A, Mathioudakis A, Vestbo J, Singh D. COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. Eur Respir Rev. 2020 Dec 31;29(158). doi:10.1183/16000617.0199-2020.
  • Singh J, Malik P, Patel N, Pothuru S, Israni A, Chakinala RC, Hussain MR, Chidharla A, Patel H, Patel SK. et al. Kidney disease and COVID-19 disease severity—systematic review and meta-analysis. Clin Exp Med. 2022 Feb 1;22(1):125–35. doi:10.1007/s10238-021-00715-x.
  • Jorgensen S, Burry L, Tabbara N. Role of maternal COVID-19 vaccination in providing immunological protection to the newborn. Pharmacotherapy. 2022 Jan 1;42(1):58–70. doi:10.1002/phar.2649.
  • Nana M, Nelson-Piercy C. COVID-19 in pregnancy. Clin Med. 2021 Sept 1;21(5):e446–50. doi:10.7861/clinmed.2021-0503.
  • Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ-Brit Med J. 2009 Jun 29;338:b2393. doi:10.1136/bmj.b2393.
  • Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, Olson SM, Talbot HK, Casey JD, Mohr NM, et al. Comparative effectiveness of moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions — United States, March–August 2021. MMWR-Morbid Mortal W. 2021 Sept 24;70(38):1337–43. doi:10.15585/mmwr.mm7038e1.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.